BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million

BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Firm”), a clinical-stage biotechnology firm specializing in focused immunotherapies for superior breast most cancers, right this moment introduced that it has accomplished the sale of a further 882,352 shares on the public providing value of US$4.24 per share pursuant to the underwriter’s over-allotment choice granted in reference to the Firm’s current public providing, leading to further gross proceeds of roughly US$3.7 million. After giving impact to the total train of the over-allotment choice, the whole gross proceeds for the general public providing elevated to roughly US$28.7 million.

ThinkEquity, a division of Fordham Monetary Administration, Inc., acted as sole book-running supervisor for the providing.

The Firm intends to make use of the web proceeds to fund scientific trials and analysis and growth and for normal working capital and normal company functions.

A registration assertion on Type F-1 (File No. 333-234292) regarding the providing was filed with the Securities and Change Fee (“SEC”) and declared efficient on February 23, 2021. The providing was made solely by the use of a prospectus. Copies of the ultimate prospectus could also be obtained from ThinkEquity, a division of Fordham Monetary Administration, Inc., 17 State Road, 22nd Flooring, New York, New York 10004, by phone at (877) 436-3673, or by electronic mail at Buyers may additionally get hold of these paperwork for gratis by visiting the SEC’s web site at

No securities regulatory authority has both accredited or disapproved the contents of this information launch. This press launch shall not represent a proposal to promote or a solicitation of a proposal to purchase, nor shall there be any sale of those securities in any state or jurisdiction by which such a proposal, solicitation, or sale can be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology targeted biotechnology firm growing focused and efficient approaches for the administration of most cancers.

For added data on BriaCell, please go to:

Ahead Trying Statements

This press launch comprises “forward-looking statements” which are topic to substantial dangers and uncertainties. All statements, apart from statements of historic reality, contained on this press launch are forward-looking statements. Ahead-looking statements contained on this press launch could also be recognized by way of phrases reminiscent of “anticipate,” “imagine,” “ponder,” “might,” “estimate,” “anticipate,” “intend,” “search,” “might,” “may,” “plan,” “potential,” “predict,” “challenge,” “goal,” “purpose,” “ought to,” “will” “would,” or the unfavorable of those phrases or different comparable expressions, though not all forward-looking statements comprise these phrases. Ahead-looking statements are primarily based on BriaCell’s present expectations and are topic to inherent uncertainties, dangers and assumptions which are tough to foretell. Additional, sure forward-looking statements are primarily based on assumptions as to future occasions that won’t show to be correct. These and different dangers and uncertainties are described extra totally within the part titled “Danger Components” within the Firm’s SEC filings. Ahead-looking statements contained on this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no obligation to replace such data besides as required underneath relevant regulation.

Neither TSX Enterprise Change nor its Regulation Providers Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Change) accepts accountability for the adequacy or accuracy of this launch.

Contact Info

Firm Contact:
William V. Williams, MD
President & CEO

Media Relations:
Jules Abraham
Director of Public Relations

Investor Relations Contact:

Finance news

Follow by Email